Bristol-Myers Squibb Co (BMY) Stock Analysis

Verdict: HOLD

Robust FCF yield of 8.9% and 4.58% dividend support valuation, but revenue patent cliffs in 2028-2029 limit upside potential.

Investment score: 63/100

Analysis as of

Is Bristol-Myers Squibb Co stock worth reviewing? The TradeMates thesis

The TradeMates model rates Bristol-Myers Squibb as a HOLD. Low earnings valuation (13.88x P/E) and dependable free cash flow ($12.85B in 2025) protect the 4.58% dividend yield, but impending 2028 patent cliffs cap upside momentum.

7-factor investment score

Bristol-Myers Squibb Co opportunities and risks

What speaks for BMY

What speaks against BMY

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
BMY13.9x2.6x9.7x70.2%18.9%8.9%
LLY43.7x15.4x29.5x83.4%33.5%1.6%
JNJ40.6x6.5x21.8x68.8%16.2%3.2%
MRK116.9x5.5x29.5x75.4%4.8%4.4%
PFE40.2x2.7x17.5x71.3%6.8%6.3%
RPRX26.4x11.2x21.3x89.4%32.1%10.5%
Peer median40.6x6.5x21.8x75.4%16.2%4.4%

Frequently asked questions about Bristol-Myers Squibb Co (BMY)

Is BMY stock a good investment?

The TradeMates model rates Bristol-Myers Squibb Co as HOLD with an investment score of 63/100. The TradeMates model rates Bristol-Myers Squibb as a HOLD. Low earnings valuation (13.88x P/E) and dependable free cash flow ($12.85B in 2025) protect the 4.58% dividend yield, but impending 2028 patent cliffs cap upside momentum. This is algorithmic model output, not personal investment advice.

Is BMY stock a buy?

The TradeMates model verdict for BMY is HOLD with an investment score of 63/100. Treat this as a model signal to review, not a personal buy recommendation.